Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR

Key Points

• Bank of America sharply increased its Vor Biopharma stake by 28,408.1% in the first quarter, holding 112,892 shares worth approximately $2.01 million. Institutional investors and hedge funds collectively own 97.29% of the stock.
• Analyst sentiment is broadly positive, with Vor Biopharma receiving a “Moderate Buy” consensus rating and an average price target of $43.38; individual targets include HC Wainwright’s $31 and Wedbush’s raised $27 target.
• Vor Biopharma shares opened at $24.76, but the company reported a quarterly loss of $0.80 per share, missing estimates of a $0.69 loss. Its lead program, VOR33, is being developed for relapsed or refractory AML and high-risk MDS.

Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ:VOR - Free Report) by 28,408.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 112,892 shares of the company's stock after purchasing an additional 112,496 shares during the quarter. Bank of America Corp DE owned approximately 0.21% of Vor Biopharma worth $2,014,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of VOR. Squarepoint Ops LLC acquired a new stake in shares of Vor Biopharma in the third quarter valued at approximately $230,000. BNP Paribas Financial Markets increased its holdings in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock worth $296,000 after acquiring an additional 5,058 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Vor Biopharma in the 3rd quarter valued at $304,000. Susquehanna Portfolio Strategies LLC bought a new stake in Vor Biopharma in the 4th quarter valued at $134,000. Finally, Persistent Asset Partners Ltd bought a new stake in Vor Biopharma in the 4th quarter valued at $141,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen raised shares of Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Wedbush upped their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings raised shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.38.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $24.76 on Thursday. The stock's fifty day moving average price is $20.92 and its two-hundred day moving average price is $16.93. Vor Biopharma Inc. has a one year low of $6.50 and a one year high of $49.95.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). As a group, equities research analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source